Development and validation of nomograms for predicting overall and breast cancer-specific survival among patients with triple-negative breast cancer

References

• FitzmauriceCDickerDPainAThe global burden of cancer 2013 global burden of disease cancer collaborationJama Oncol20151450552726181261
   PubMed Web of Science ®Google Scholar
• HammondMEHayesDFDowsettMAmerican Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancerArch Pathol Lab Med2010134690792220524868
   PubMed Web of Science ®Google Scholar
• AndreopoulouESchweberSJSparanoJAMcDaidHMTherapies for triple negative breast cancerExpert Opin Pharmacother201516798399825881743
   PubMed Web of Science ®Google Scholar
• FoulkesWDSmithIEReis-FilhoJSTriple-negative breast cancerN Engl J Med2010363201938194821067385
   PubMed Web of Science ®Google Scholar
• DentRTrudeauMPritchardKITriple-negative breast cancer: clinical features and patterns of recurrenceClin Cancer Res20071315 Pt 14429443417671126
   PubMed Web of Science ®Google Scholar
• WangSLLiYXSongYWTriple-negative or HER2-positive status predicts higher rates of locoregional recurrence in node-positive breast cancer patients after mastectomyInt J Radiat Oncol Biol Phys20118041095110120638197
   PubMed Web of Science ®Google Scholar
• MontagnaEMaisonneuvePRotmenszNHeterogeneity of triple-negative breast cancer: histologic subtyping to inform the outcomeClin Breast Cancer2013131313923098574
   PubMed Web of Science ®Google Scholar
• DentRTrudeauMPritchardKITriple-negative breast cancer: clinical features and patterns of recurrenceClin Cancer Res20071315 Pt 14429443417671126
   PubMed Web of Science ®Google Scholar
• CareyLAPerouCMLivasyCARace, breast cancer subtypes, and survival in the Carolina Breast Cancer StudyJAMA2006295212492250216757721
   PubMed Web of Science ®Google Scholar
• FineJPGrayRJA proportional hazards model for the subdistribution of a competing riskJ Am Stat Assoc199994446496509
   Web of Science ®Google Scholar
• GrayRJA Class of $K$-sample tests for comparing the cumulative incidence of a competing riskThe Annals of Statistics198816311411154
   Web of Science ®Google Scholar
• KimEKNohWCHanWNohDYPrognostic significance of young age (<35 years) by subtype based on ER, PR, and HER2 status in breast cancer: a nationwide registry-based studyWorld J Surg20113561244125321472372
   PubMed Web of Science ®Google Scholar
• LiedtkeCHessKRKarnTThe prognostic impact of age in patients with triple-negative breast cancerBreast Cancer Res Treat2013138259159923460246
   PubMed Web of Science ®Google Scholar
• AzimHAMichielsSBedardPLElucidating prognosis and biology of breast cancer arising in young women using gene expression profilingClin Cancer Res20121851341135122261811
   PubMed Web of Science ®Google Scholar
• BauerKRBrownMCressRDPariseCACaggianoVDescriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer RegistryCancer200710991721172817387718
   PubMed Web of Science ®Google Scholar
• AmbrosoneCBZirpoliGRuszczykMParity and breastfeeding among African-American women: differential effects on breast cancer risk by estrogen receptor status in the Women’s Circle of Health StudyCancer Causes Control201425225926524249438
   PubMed Web of Science ®Google Scholar
• BrewsterAMChavez-MacgregorMBrownPEpidemiologyBPEpidemiology, biology, and treatment of triple-negative breast cancer in women of African ancestryLancet Oncol20141513e625e63425456381
   PubMed Web of Science ®Google Scholar
• KeenanTMoyBMrozEAComparison of the genomic landscape between primary breast cancer in African American versus white women and the association of racial differences with tumor recurrenceJ Clin Oncol201533313621362726371147
   PubMed Web of Science ®Google Scholar
• LundMJTriversKFPorterPLRace and triple negative threats to breast cancer survival: a population-based study in Atlanta, GABreast Cancer Res Treat2009113235737018324472
   PubMed Web of Science ®Google Scholar
• BauerKRBrownMCressRDPariseCACaggianoVDescriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer RegistryCancer200710991721172817387718
   PubMed Web of Science ®Google Scholar
• CareyLAPerouCMLivasyCARace, breast cancer subtypes, and survival in the Carolina Breast Cancer StudyJAMA2006295212492250216757721
   PubMed Web of Science ®Google Scholar
• SachdevJCAhmedSMirzaMMFarooqAKronishLJahanzebMDoes race affect outcomes in triple negative breast cancer?Breast Cancer20104233320697530
   PubMedGoogle Scholar
• AminMBGreeneFLEdgeSBThe Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more “personalized” approach to cancer stagingCA Cancer J Clin2017672939928094848
   PubMed Web of Science ®Google Scholar
• PerouCMSørlieTEisenMBMolecular portraits of human breast tumoursNature2000406679774775210963602
   PubMed Web of Science ®Google Scholar
• ParkYHLeeSJChoEYClinical relevance of TNM staging system according to breast cancer subtypesAnn Oncol20112271554156021242587
   PubMed Web of Science ®Google Scholar
• GiulianoAEEdgeSBHortobagyiGNEighth edition of the AJCC cancer staging manual: breast cancerAnn Surg Oncol20182571783178529671136
   PubMed Web of Science ®Google Scholar
• GiulianoAEConnollyJLEdgeSBBreast Cancer-Major changes in the American Joint Committee on Cancer eighth edition cancer staging manualCA Cancer J Clin201767429030328294295
   PubMed Web of Science ®Google Scholar
• BagariaSPRayPSSimMSPersonalizing breast cancer staging by the inclusion of ER, PR, and HER2JAMA Surg2014149212512924306257
   PubMed Web of Science ®Google Scholar